<doc>
  <docmeta id="113hr4187ih">
    <bill congress="113" type="hr" number="4187" version="ih"/>
    <revision size="6053" annotations="0" status="complete" id="4" commit-time="2014-03-17T19:07:10Z" committer="mbohmer" doc="113hr4187ih/4.xml">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H075BD7DBBAAB47F9AE15EB6FDB2E9636" public-private="public">
	<metadata>
<dublinCore>
<dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">113 HR 4187 IH: Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014</dc:title>
<dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">U.S. House of Representatives</dc:publisher>
<dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2014-03-11</dc:date>
<dc:format xmlns:dc="http://purl.org/dc/elements/1.1/">text/xml</dc:format>
<dc:language xmlns:dc="http://purl.org/dc/elements/1.1/">EN</dc:language>
<dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/">Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>2d Session</session>
		<legis-num>H. R. 4187</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20140311">March 11, 2014</action-date>
			<action-desc>
        <sponsor name-id="R000580">Mr. Roskam</sponsor> (for himself and <cosponsor name-id="D000096">Mr. Danny K. Davis of Illinois</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HWM00">Committee on Ways and Means</committee-name>, and in addition to the Committee on <committee-name committee-id="HIF00">Energy and Commerce</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such
			 provisions as fall within the jurisdiction of the committee concerned</action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend title XVIII of the Social Security Act to encourage the development and use of new
			 antimicrobial drugs, and for other purposes.</official-title>
	</form>
	<legis-body id="H73AE25BCFBCD420FAE6F6E0BA1EC45F9" style="OLC">
		<section id="H54F6C21DF19144DBB8F3F700EE2DF507" section-type="section-one">
      <enum>1.</enum>
      <header>Short title</header>
      <text display-inline="no-display-inline">This Act may be cited as the <quote>
          <short-title>
            <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014" proposed="true">Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014</cato:entity-ref>
          </short-title>
        </quote> and as the <quote>
          <short-title>DISARM Act of 2014</short-title>
        </quote>.</text>
		</section>
    <section id="HF052E85DC75C469BA9F66B65B1A1FEB8">
      <enum>2.</enum>
      <header>Encouraging the development and use of new antimicrobial drugs</header>
			<subsection id="H510E3E491D3840B4908C11E65475358D">
        <enum>(a)</enum>
        <header>Additional payment for new antimicrobial drugs under Medicare</header>
				<paragraph id="H1D0D6F61787046159CFBBA17A38EF3A8">
          <enum>(1)</enum>
          <header>In general</header>
          <text>
            <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Social Security Act/s:1886/ss:d/p:5">Section 1886(d)(5) of the Social Security Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/42/1395ww">
              <cato:entity-ref entity-type="uscode" value="usc/42/1395ww/d/5">42 U.S.C. 1395ww(d)(5)</cato:entity-ref>
            </external-xref>)</cato:entity> is amended by adding at the
			 end the following new subparagraph:</text>
					<quoted-block display-inline="no-display-inline" id="HD361DBA67E864287ACF99D5DF2A2B7A3" style="OLC">
						<subparagraph id="HF0DCBA92B3574338A640B3E2309EF3EC" indent="up2">
              <enum>(M)</enum>
							<clause commented="no" display-inline="yes-display-inline" id="H1F92A984F6174CA68AA1639B36CCA4B3">
                <enum>(i)</enum>
                <text display-inline="yes-display-inline">Effective for discharges beginning on or after October 1, 2014, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall, after notice
			 and opportunity for public comment (in the publications required by
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1886/ss:e/p:5">subsection (e)(5)</cato:entity-ref> for a fiscal year or otherwise), recognize the costs of
			 new antimicrobial drugs under the payment system established under this
			 subsection.</text>
							</clause>
              <clause id="HE21AC7A55FA9427DA6ED746D310044F0" indent="up1">
                <enum>(ii)</enum>
                <text display-inline="yes-display-inline">Pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1886/ss:d/p:5/sp:M/cl:i" proposed="true">clause (i)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall provide for additional payment to be made under this
			 subsection with respect to discharges involving new antimicrobial drugs in
			 the amount provided for under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1847A">section 1847A</cato:entity-ref> for drugs and biologicals that
			 are described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1842/ss:o/p:1/sp:C">section 1842(o)(1)(C)</cato:entity-ref>.</text>
							</clause>
              <clause id="H9EAA684BFA5E4F25ABDB2FD0A4E1D6C0" indent="up1">
                <enum>(iii)</enum>
                <text display-inline="yes-display-inline">For purposes of this subparagraph, the term <term>new antimicrobial drug</term> means a product that is approved for use, or a product for which an indication is first approved
			 for use, by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Federal Food and Drug Administration</cato:entity-ref> on or after January
			 1, 2014, and that—</text>
								<subclause id="H266F13C2AE5B41CD838945136293E296">
                  <enum>(I)</enum>
                  <text display-inline="yes-display-inline">is indicated to treat an infection caused by, or likely to be caused by, a qualifying pathogen (as
			 defined under <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                      <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505E/ss:f">section 505E(f) of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref>
			 (<external-xref legal-doc="usc" parsable-cite="usc/21/355f">
                      <cato:entity-ref entity-type="uscode" value="usc/21/355f/f">21 U.S.C. 355f(f)</cato:entity-ref>
                    </external-xref>)</cato:entity>) for which there is an unmet medical need and which is
			 associated with high rates of mortality or significant patient morbidity
			 (as determined by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, in consultation with the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7523">Director of the
			 Centers for Disease Control and Prevention</cato:entity-ref> and the infectious disease
			 professional community); and</text>
								</subclause>
                <subclause id="H30891E5F0C5C43D7B1E4880A84968A5F">
                  <enum>(II)</enum>
                  <text display-inline="yes-display-inline">is used in facilities that participate in the Antimicrobial Use and Resistance Module of the
			 National Healthcare Safety Network of the Centers for Disease Control and
			 Prevention (or, in the case that such Module is not available, is used in
			 facilities that participate in such successor or similar reporting module
			 or program relating to antimicrobials as the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall specify to
			 the extent available to such facilities, as determined by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>).</text>
								</subclause>
              </clause>
              <clause id="H613FFE2CD4E34A47B76D88417D7267BE" indent="up1">
                <enum>(iv)</enum>
                <text>Not later than July 1, 2014, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall first publish in the Federal Register a list of
			 the new antimicrobial drugs.</text>
							</clause>
            </subparagraph>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
				</paragraph>
        <paragraph id="HCE19341245B945BA89EEAC1170A1BC67">
          <enum>(2)</enum>
          <header>Budget neutrality</header>
          <text>
            <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Social Security Act/s:1886/ss:d/p:3/sp:C">Section 1886(d)(3)(C) of the Social Security Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/42/1395ww">
              <cato:entity-ref entity-type="uscode" value="usc/42/1395ww/d/3/C">42 U.S.C. 1395ww(d)(3)(C)</cato:entity-ref>
            </external-xref>)</cato:entity> is amended by adding
			 at the end the following new clause:</text>
					<quoted-block display-inline="no-display-inline" id="H965CC15A30084A269C34445237FB9D82" style="OLC">
						<clause id="HC010F57066ED4273BBEDEB69C8518FC2" indent="up2">
              <enum>(iii)</enum>
              <header>Maintaining budget neutrality for certain antimicrobial drugs</header>
              <text display-inline="yes-display-inline">For discharges occurring in a fiscal year beginning with fiscal year 2015, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall
			 further reduce each of the average standardized amounts in an amount equal
			 to the amount of the net additional expenditures, if any, in such fiscal
			 year resulting from the application of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1886/ss:d/p:5/sp:M" proposed="true">paragraph (5)(M)</cato:entity-ref>.</text>
            </clause>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
				</paragraph>
      </subsection>
      <subsection id="H68D80C9BA79247788488F86F0782FA05">
        <enum>(b)</enum>
        <header>Study and report on removing barriers to development of new antimicrobial drugs</header>
				<paragraph id="H1B62E06749244BECAD72A59379593461">
          <enum>(1)</enum>
          <header>Study</header>
          <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0500">Comptroller General of the United States</cato:entity-ref> shall, in consultation with the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1344">Director of the United
			 States Patent and Trademark Office</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7529">Director of the National
			 Institutes of Health</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Commissioner of Food and Drugs</cato:entity-ref>, and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7523">Director
			 of the Centers for Disease Control and Prevention</cato:entity-ref>, conduct a study to—</text>
					<subparagraph id="H0C56C30654E44642A8787649B97B3099">
            <enum>(A)</enum>
            <text>identify and examine the barriers that prevent the development of new antimicrobial drugs, as
			 defined in <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                <cato:entity-ref entity-type="act" value="Social Security Act/s:1886/ss:d/p:5/sp:M/cl:iii" proposed="true">section 1886(d)(5)(M)(iii) of the Social Security Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/42/1395ww/d/5/M/iii" proposed="true">42
			 U.S.C. 1395ww(d)(5)(M)(iii)</cato:entity-ref>)</cato:entity>; and</text>
					</subparagraph>
          <subparagraph id="HB255A8ED70774A3383D841E365BBE1CA">
            <enum>(B)</enum>
            <text>develop recommendations for actions to be taken in order to overcome any barriers identified under
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014/s:2/ss:b/p:1/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>.</text>
					</subparagraph>
        </paragraph>
        <paragraph id="H92583E8C619647FDB3D3F5399DFEC4AC">
          <enum>(2)</enum>
          <header>Report</header>
          <text display-inline="yes-display-inline">Not later than one year after the date of the enactment of this Act, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0500">Comptroller General</cato:entity-ref> shall
			 submit to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref> a report on the study conducted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014/s:2/ss:b/p:1" proposed="true">paragraph (1)</cato:entity-ref>.</text>
				</paragraph>
      </subsection>
    </section>
  </legis-body>
</bill>
</doc>